Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cerveau is a multi-ingredient dietary supplement developed by Sanus Biotech, designed to support brain health and cognitive function. The formula contains a comprehensive blend of amino acids, vitamins, and botanical extracts, including Vitamin B6, L-Tyrosine, L-Glutamine, Rhodiola Rosea, 5-HTP (oxitriptan), DL-Phenylalanine, Passion flower, N-Acetyl-Cysteine, Arabinogalactan, Mucuna pruriens, L-Theanine, D-Ribose, Phosphatidylserine, and SAM-E (s-adenosylmethionine). Cerveau is intended to improve focus, energy, and mood by providing metabolic precursors for neurotransmitter synthesis, specifically targeting the serotonin and dopamine systems. It was administered as a chewable tablet designed for sublingual absorption to facilitate rapid delivery of its active components. Although the developer, Sanus Biotech, is no longer active, the product was marketed for the reduction of anxiety and the enhancement of overall well-being.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cerveau.